Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period ActivityBusiness Wire • 08/01/24
Seeking Clues to Alnylam (ALNY) Q2 Earnings? A Peek Into Wall Street Projections for Key MetricsZacks Investment Research • 07/30/24
Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial ResultsBusiness Wire • 07/18/24
35% Surge Just the Beginning? Alnylam's Stock Poised for Massive Gains on Heart Drug Success.InvestorPlace • 07/11/24
Alnylam's Closely Watched Phase 3 Heart Disease Trial Of Vutrisiran Hits Primary Endpoint, Shares SurgeBenzinga • 06/24/24
Alnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart DrugInvestors Business Daily • 06/24/24
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy PopulationsBusiness Wire • 06/24/24